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Summary  The  emergence  of  drug  resistance  is  a  major  problem  for  tuberculosis
(TB)  control.  The  aim  of  this  study  was  to  determine  the  rates  of  resistance  against
TB  drugs  in  patients  with  pulmonary  tuberculosis  (PTB).  Data  from  387  patients
with  active  PTB  between  the  years  of  1999  and  2004  from  the  Research  and  Educa-
tion  Hospital  for  Chest  Diseases  and  Chest  Surgery  were  evaluated  retrospectively.
The  patients  were  categorized  as  new,  re-treatment,  extrapulmonary  and  chronic
cases.  The  study  group  consisted  of  268  (69%)  new,  57  (14.7%)  re-treatment,  49
(12.6%)  extrapulmonary  and  13  (3.3%)  chronic  TB  cases.  The  rates  of  resistance
to  isoniazid  (INH),  rifampicin  (R),  ethambutol  (E)  and  streptomycin  (S)  were  cal-
culated  separately  for  each  group.  The  resistance  to  any  of  the  drugs  was  7.8%
in  the  new  cases,  58.5%  in  the  re-treatment  cases  and  100%  in  the  chronic  cases.
The  multidrug-resistance  (MDR)-TB  rates  were  found  to  be  2.16%,  11.3%  and  92.3%
among  the  new,  re-treatment  and  chronic  cases,  respectively.  These  data  are  impor-
tant  as  they  reﬂect  the  drug  resistance  rates  during  the  pre-notiﬁcation  time  period
in  western  Turkey.
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nfection  with  various  clinical  manifestations.  The
ycobacterium  tuberculosis  complex  (M.  tuber-
ulosis,  M.  bovis,  M.  canetti,  M.  africanum, M.
 Sciences. Published by Elsevier Ltd. All rights reserved.
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1999  22,088  32.9  18,752  3336  79.9  27.5  84.9
2000  18,038  26.4  17,230  808  75.8  37.5  95.5
2001  18,890  27.3  17,263  1627  74.4  34.6  91.4
2002  19,028  27.1  16,376  2652  73.9  43.2  86
2003  18,590  26.1 17,923  667  69.3  45.1  96.4
2004  19,799  27.4 17,510  2289  71.9  46.6  88.4


































































wa Percentage of pulmonary cases among all cases.
b Percentage of new cases among all cases.
icroti,  M.  caprea,  M.  pinnipedii  and  M.  mungi)
s responsible  for  TB.  M.  tuberculosis  (MTB)  causes
7—99%  of  TB  cases.  More  than  80%  of  TB  cases  take
he form  of  pulmonary  TB  (PTB)  [1,2].
TB is  one  of  the  most  common  infectious  dis-
ases. According  to  the  World  Health  Organization
WHO), 14  million  prevalent  and  9.4  million  incident
ases of  TB  were  recorded  worldwide  in  2009.  TB
s responsible  for  approximately  1.7  million  deaths
nnually  [3,4].
The  emergence  of  resistant  strains  of  MTB  rep-
esents a  real  threat  to  successful  global  TB  control
nd elimination.  Drug  resistance  was  ﬁrst  recog-
ized  as  a  major  problem  in  1992,  when  12%  of
he TB  patients  in  New  York  City  were  found  to
xhibit multidrug-resistant  TB  (MDR-TB).  As  a  result
f inadequate  TB  control  programs,  improper  pro-
ective measures  against  infection  and  delayed
iagnosis of  TB,  MDR-TB  has  spread  throughout  the
orld [5—8].
The  prevention  and  control  of  drug-resistant  TB
hould  be  emphasized  in  control  programs  through
easures  such  as  prompt  detection,  application
f the  routine  quality-assured  drug  susceptibil-
ty test  for  patients  at  high  risk  of  resistance,  a
ational  treatment  plan  for  both  ﬁrst-and  second-
ine medicines  and  the  systematic  observation
f treatment  [4,8].  Resistance  among  new  cases
ndicates  direct  transmission  of  drug-resistant
TB. Resistance  rates  generally  increase  rapidly
hen resistance  among  previously  treated  cases  is
lready high  and  when  conditions  for  the  spread  of
he disease  are  favorable.
In  Turkey  in  2009,  the  incidence  of  TB  was
eported to  be  29  per  100,000  individuals,  and
he recorded  fatality  rate  was  3%  for  TB  patients.
pidemiological  data  for  Turkey  during  the  study
eriod  are  provided  in  Table  1  [5,10].
The objective  of  the  study  was  to  determine  the
ate of  resistance  to  anti-TB  drugs  in  patients  cate-




teferral  hospital  for  chest  diseases  during  the  ﬁve
ears between  1999  and  2004.
ethods
he  rates  of  resistance  to  isoniazid  (INH),  rifampicin
R), ethambutol  (E)  and  streptomycin  (S)  were  ana-
yzed in  387  male  patients  with  active  pulmonary
uberculosis who  were  treated  between  1999  and
004 at  the  Izmir  Training  Hospital  for  Chest  Dis-
ases and  Chest  Surgery.  The  cases  were  retrieved
rom the  patient  ﬁles  in  the  hospital  archive  and
aboratory  records  and  were  categorized  into  three
roups:  new,  re-treated  and  chronic  cases.  Sputum
nd other  respiratory  secretions  (induced  sputum,
ronchial  aspiration  and  bronchoalveolar  lavage
uid) were  examined  through  smears  and  culturing
or  MTB.  The  duration  of  basal  conversion  and  the
ength of  stay  in  the  hospital  were  evaluated.  Basal
onversion  was  investigated  by  examining  micro-
copic smears  from  the  patients  on  a  weekly  basis
nd cultures  on  monthly  basis  during  hospitaliza-
ion. After  discharge,  culture  and  smear  controls
ere performed  on  a  monthly  basis.
The  case  deﬁnitions  were  in  accordance  with  the
ational TB  and  WHO  guidelines  [5,9].
Cases of  relapse,  treatment  failure  and  treat-
ent after  interruption  were  evaluated  in  the
e-treatment group.
Microscopic  smears  were  stained  using  the
inyoun method.  N-acetyl-L-cysteine  (NALC)  plus
odium  hydroxide  (NaOH)  was  employed  for  decon-
amination  and  homogenization.  Lowenstein—
ensen (L—J)  Medium  and  the  BACTEC  960  system
ere used  for  the  isolation  of  TB  bacilli.  TB  drug
usceptibility testing  was  performed  following  the
ritical proportion  method  and  critical  concen-
ration method,  which  is an  economic  variant  of
he proportion  method  conducted  on  L—J,  using  a
278  B.  Komurcuoglu  et  al.
Table  2  Case  numbers  and  microbiological  characteristics  of  the  study  groups.
Smear  (−)  Culture  (+)  N  (%)  Smear  (+)  culture  (+)  N  (%)  Resulting  DST  N  (%)
New  casesa (n  =  268)  40  (14.9)  228  (85.1)  231  (86.2)
Re-treatment  casesb (n  =  57)  28  (49.1)  29  (50.9)  53  (93)
Chronic  cases  (n  =  13)  0  13  (100)  13  (100)
Total  (n  =  338)  68  (20.1)  270  (79.9)  297  (87.9)


































ra Smear (+) pulmonary-TB, Smear (−) pulmonary-TB.
b Relapse, treatment failure, treatment after interruption.
BACTEC  460  semi-automatic  system  [11,12]. Anti-
TB drug  susceptibility  tests  (DSTs)  were  repeated
for each  isolate  for  conﬁrmation  of  DST  results.
Between  1999  and  2003,  internal  quality  control
was performed  using  the  M.  tuberculosis  H37  Ra
and H37Rv  strains  for  culture  and  daily  DST.  The
external  quality  control  system  has  been  employed
since 2004  by  the  UK  National  External  Quality
Assessment System  (NEQAS)  for  smear  and  culture
conﬁrmation.  The  EQ  for  drug  susceptibility  testing
was begun  in  2005  through  ‘‘Lot  Quality  Assurance
Sampling’’ (LQAS)  in  a  national  third-level  TB  labo-
ratory.
Drug regimens  were  designed  for  both  the  new
and re-treatment  cases  following  WHO  recommen-
dations [9].
The  drug  resistance  classiﬁcations  were  deter-
mined according  to  the  WHO  guidelines  as  given
below:
Total resistance  —  any  resistance  to  an  anti-TB
drug alone  and  combined  with  other  drugs.
Mono-resistance  —  resistance  to  one  of  the  ﬁrst-
line drugs  (INH,  R,  E  or  S).
Multidrug-resistant  tuberculosis  (MDR-TB)  —  resis-
tance to  at  least  INH  and  R.
Poly-resistance  (other  patterns)  —  resistance  to
two or  more  ﬁrst-line  drugs,  not  including  the  INH
and R  combination  [5].
The chi-square  test  in  the  SPSS  program  on  a
personal  computer  was  used  for  statistical  analysis
[13].
This  study  was  approved  by  the  hospital  ethics
committee.
Results
A  total  of  387  patients  with  active  PTB  from  our
clinic  were  evaluated  over  a  ﬁve-year  period.  All
of the  patients  were  male,  and  their  mean  age
was 23.7  ±  5.65  years.  Culture-negative  and  extra-
pulmonary  cases  (n  = 49)  were  excluded  from  this
study,  while  bacteriologically  positive  PTB  cases
r
s
tn =  338)  were  included.  The  numbers  of  cases
ccording to  groups  and  drug  resistance  rates  are
rovided in  Tables  2  and  3.
Both cultures  and  smears  were  found  to  be  pos-
tive in  a  total  of  270  (70%)  of  the  cases.  The
mear-negative/culture-positive  combination  was
ound in  68  cases  (17.5%).  Cultures  and  smears  were
oth negative  in  49  (12.6%)  of  the  cases.  DSTs  were
erformed,  and  drug  susceptibility  was  determined
or 297  of  the  338  culture-positive  cases  (89%).  A
otal of  91.1%  and  41.5%  of  isolates  from  new  and
e-treatment  cases,  respectively,  were  found  to  be
usceptible  to  all  of  the  tested  anti-tuberculosis
rugs. All  of  the  isolates  from  chronic  cases  were
esistant to  at least  one  drug.  Multidrug  resistance
atterns were  found  in  2.16%,  11.3%  and  92.3%  of
he new,  re-treatment  and  chronic  cases,  respec-
ively.
The  mean  basal  conversion  times  were  deter-
ined to  be  3.2  ±  2.3  weeks,  6.3  ±  3.3  weeks  and
6 months  for  the  new,  re-treatment  and  chronic
ases, respectively.  Similarly,  the  length  of  stay
as 5.4  ±  3.1  weeks,  8.9  ±  5.5  weeks  or  6.2  ±  2.1
onths  for  the  new,  re-treatment  and  chronic
ases, respectively.
All patients  were  HIV  negative.
iscussion
rug  resistance  in  TB  leads  to  a signiﬁcantly
ncrease in  morbidity,  mortality  and  treatment
osts [5,14,15].  Control  programs  for  TB  should
nclude  the  rational  management  of  TB  drug  resis-
ance. The  management  of  drug  resistance  requires
he surveillance  of  resistant  cases.  Many  studies
ave been  performed  on  the  rates  of  TB  drug
esistance in  Turkey  [16—25]. However,  new  and
e-treatment  cases  have  not  been  reported  sepa-
ately in  most  national  studies.  Instead,  combined
esistance rates  are  generally  given.
The  WHO  has  conducted  drug  resistance  surveys
ince 1994.  According  to  recent  data  on  resistance,
he resistance  to  one  drug  is  between  0%  and  56%
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Table  3  TB  drug  resistance  rates  in  the  study  groups.
All  cases
N =  297  (%)
New  cases
N  =  231  (%)
Re-treatment
cases  N  =  53  (%)
Chronic  cases
N  =  13  (%)
Susceptible  to  all  drugs  234  (79)  212  (91.1)  22  (41.5)  0
Total  resistance
INH  38  (12)  10  (4.3)  16  (30.1)  12  (92.3)
R  44  (14)  9  (4.2)  22  (41.5)  13  (100)
E  19  (6) 6  (2.6) 6  (11.3) 7  (53.8)
S  29  (9.7) 8  (3.4) 13  (24.5) 8  (61.5)
Mono-resistance
INH  7  (2.3)  3  (1.3)  4  (7.5)  0
R  4  (1.4)  1  (0.4)  3  (5.7)  0
E  4  (1.4)  2  (0.8)  2  (3.8)  0
S  5  (1.6)  2  (0.8)  3  (5.6)  0
Multidrug  resistance  (MDR)  patterns
INH  +  R  11  (3.7)  2  (0.8)  6  (11.3)  3  (23)
INH  +  R  +  E  3  (1)  1  (0.8)  0  2  (15.3)
INH  +  R  +  S  3  (1)  1  (0.8)  0  2  (15.3)
INH  +  R  +  E  +  S  6  (2)  1  (0.8)  0  5  (38.4)
Total  23  (7.7) 5  (2.16)  6  (11.3)  12  (92.3)
Other  resistance  patterns
INH  +  E  1  (0.3)  0  1  (1.9)  0
INH  +  S  5  (1.7)  2  3  (5.6)  0
INH  +  E  +  S  2  (0.7)  0  2  (3.8)  0
R  +  E  1  (0.3)  1  0  0
R  +  S  9  (3.2)  2  6  (11.3)  1  (7.7)












































6E  +  S  1  (0.3)  0
n  new  cases,  and  the  prevalence  of  MDR-TB  cases
s between  0%  and  22.3%  in  Baku  City,  Azerbai-
an [5].  Resistance  rates  to  one  drug  have  been
ound to  be  between  0%  and  85%,  and  MDR-TB  is
etected  in  between  0%  and  62%  or  re-treatment
ases worldwide.  In  the  new  cases  reported  in  this
tudy, the  rate  of  resistance  to  one  drug  was  7.8%,
hile this  rate  was  58.5%  in  the  re-treated  cases
nd 100%in  the  chronic  cases.  The  weighted  means
f single-drug  resistance  found  for  INH,  R,  E,  and
 and  for  MDR-TB  are  17%  10.3%,  3.7%,  10.9%,  2.5%
nd 2.9%  among  new  cases  and  35%,  27.7%,  17.5%,
0.1%,  10.3%  and  15.3%  among  re-treatment  cases,
espectively,  in  all  WHO  regions.  The  highest  rates
f resistance  were  observed  in  Eastern  Europe  and
ast Mediterranean  regions  [5].
According  to  data  from  the  European  Center  for
isease  Prevention  and  Control  (ECDC),  the  aver-
ge resistance  rate  against  one  drug  is  14%,  and
he MDR-TB  rate  is  2.8%  in  new  and  19.8%  in  re-
reatment cases  in  ECDC  areas.  These  rates  were
ncreased  due  to  data  from  several  Eastern  Euro-
ean countries,  such  as  Latvia  and  Estonia  [14].
Turkey has  not  conducted  a  nationwide  TB  survey




T1  (1.9)  0
as  performed  and  reported.  According  to  this
rogram,  which  provided  the  ﬁrst  ofﬁcial  national
ata, 3.1%  and  17.7%  of  3238  new  cases  and  508
e-treatment  cases,  respectively,  were  found  to
isplay MDR-TB  in  2005  [10]. Our  data  should  be
egarded  as  important  due  to  providing  information
bout the  pre-notiﬁcation  time  period.  A  compar-
son of  our  data  with  the  current  national  and
nternational data  is  presented  in  Table  4.  Atten-
ion should  be  paid  to  the  resistance  rates  observed
n the  previously  treated  cases.  Both  resistance  to
ny TB  drug  and  mono-resistance  to  R,  E and  S
ere found  to  be  higher  than  reported  national  and
lobal rates.  Furthermore,  the  rates  of  total  MDR
ere also  observed  to  be  above  published  national
nd global  rates.
In  addition  to  the  ofﬁcial  national  report  noted
bove, various  studies  have  been  published  in
urkey. Single-drug  resistance  has  been  reported  to
ange from  14%  to  17%  in  new  cases  and  37%  to
6% in  re-treatment  cases  in  Turkey  [17—25].  The
ational  resistance  data  for  Turkey  are  similar  to
ata from  the  Southeast  Asian  Region  and  the  West-
rn Paciﬁc  Region.  However,  our  data  indicated  that








Table  4  Comparison  of  national  and  global  data  with  the  study  results.
New  cases
N  =  231  (%)
Previously  treated
casesa N  =  66  (%)
National  data  (2008,
Ministry  of  Health)  [10]
Global  data
(1994—2007,  WHO)b
New  N  =  4201  (%)  Previously  treated
N  =  730  (%)
New  (%)  Previously
treated  (%)
Susceptible  to  all  drugs  212  (91.1)  22  (33.3)  3509  (83.5)  482  (66)  83  65
Total  resistance
INH  10  (4.3) 28  (42) 479  (11.3) 207  (27.9) 10.3 27.7
R  9  (4.2) 35  (53) 166  (3.9) 162  (21.8) 3.7 17.5
E  6  (2.6) 13  (19.7) 143  (3.4) 71  (9.6) 2.5 10.3
S  8  (3.4) 21  (31.8) 275  (6.5) 96  (12.9) 10.9  20.1
Mono-resistance
INH  3  (1.3)  4  (6)  261  (6.2)  47  (6.4)  —  —
R  1  (0.4) 3  (4.5) 27  (0.6) 20  (2.7) —  —
E  2  (0.8)  2  (3)  39  (0.9)  7  (1)  —  —
S  2  (0.8)  3  (4.5)  137  (3.3)  19  (2.6)  —  —
Multidrug  resistance  (MDR)  patterns
INH  +  R 2 (0.8) 9  (13.6) 47  (1.1) 59  (8.1)  —  —
INH  +  R  +  E 1 (0.8)  2  (3)  16  (0.4)  14  (1.9)  —  —
INH  +  R  +  S  1  (0.8)  2  (3)  20  (0.5)  24  (3.4)  —  —
INH  +  R  +  E  +  S  1  (0.8)  5  (7.5)  38  (0.9)  34  (4.7)  —  —
Total  MDR-TB  5  (2.16)  18  (27.3) 121  (2.9) 131  (18)  2.9  15.3
Other  resistance  patterns
INH  +  E 0 1  (1.5)  24  (0.6)  6  (0.8)  —  —
INH  +  S 2 3  (4.5)  53  (1.3)  11  (1.5)  —  —
INH  +  E  +  S 0  2  (3)  13  (0.3)  4  (0.5)  —  —
R  +  E  1  0  7  (0.2)  1  (0.1)  —  —
R  +  S  2  7  (10.6)  4  (0.1)  2  (0.3)  —  —
R  +  E  +  S  1  0  2  (0.05)  0  —  —
E  +  S  0  1  (1.5)  4  (0.1)  0  —  —































































[rug  resistance  in  pulmonary  TB  
f  the  Western  European  Region  with  respect  to
ew cases  and  to  the  Eastern  Mediterranean  Region
ith respect  to  re-treatment  cases.  This  result  may
uggest that  different  parts  of  the  country  exhibit
arying  rates  of  resistance  due  to  differences  in  the
pplication  of  TB  policy.
In various  studies  from  Turkey,  the  rates  of  INH
ono-resistance  have  been  reported  to  range  from
% to  19%  in  new  cases  and  from  8%  to  43%  in  re-
reatment cases.  In  new  cases,  R  mono-resistance
f 0.3—5.1%  and  S  mono-resistance  of  1—16%  has
een observed;  in  re-treatment  cases,  these  val-
es are  reported  to  be  6.7—35.7%  and  5.8—50%,
espectively.  Additionally,  some  studies  in  Turkey
ave found  E  mono-resistance  rates  of  1—10.7%
mong new  cases  and  3%  and  14%  in  re-treatment
ases, while  the  MDR  rate  has  been  reported  to  be
.7—7% among  new  and  4—35%  among  re-treatment
atients. Four  additional  types  of  drug  resistance
ere observed  to  range  from  0.3—1.9%  in  new  and
—5% in  re-treatment  cases  [16—25].  Among  the
hronic  cases  described  in  the  present  study,  92.3%
f the  patients  had  MDR-TB.  Only  one  patient  dis-
layed a  TB  isolate  that  not  exhibit  an  MDR  pattern.
DR-TB  was  found  in  11.3%  and  2.2%  of  the  re-
reatment and  new  cases,  respectively.  Our  data  on
esistance  to  one  drug  were  found  to  be  correlated
ith the  national  literature.
onclusion
he  management  of  drug-resistant  cases  is  a
igh priority  for  countries  in  which  a high  per-
entage of  TB  cases  are  drug  resistant,  such  as
urkey.  The  most  appropriate  approach  to  pre-
ent the  development  of  drug  resistance  is  making
apid,  high-quality  diagnostic  services  available
or prompt  case  detection;  performing  routine,
uality-assured  drug  susceptibility  tests  in  patients
t high  risk  of  resistance;  and  applying  appropri-
te treatment  in  patients  with  TB.  Improvement
f infection  control  measures  is  also  important  to
revent transmission.
In our  study  population,  the  re-treatment  cases
howed  higher  drug  resistance  rates  compared  to
eported  national  and  international  data,  while  the
rug resistance  rates  of  new  cases  were  found  to  be
ore similar  to  ofﬁcial  reports.  The  surveillance  of
rug resistance  should  be  a  high  priority  for  proper
anagement of  TB  in  our  region.
The results  of  this  study  indicate  that  investi-
ations involving  local  surveillance  can  contribute
o national  and  international  epidemiological  data.
ach such  study  increases  the  information  available
[281
or  monitoring  drug  resistance.  However,  surveil-
ance  of  R  and  INH  resistance  and  MDR-TB  has  been
eported  as  the  most  critical  indicator  of  the  efﬁ-
iency of  a TB  program  by  authorities  [26].
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